Five vitamin D studies reported in The Vitamin Professor Newsletter between May and August 2026 cover gestational diabetes, type 2 diabetes prevention in prediabetes, vitamin D deficiency in pregnancy, perimenopausal fatigue and mood, and offspring cognition at age 10. Each study summary below is reproduced verbatim from the newsletter, as written by Dr. Gene Bruno, DBM, MS, RH(AHG) [1][2][3][4].
Vitamin D appeared in four consecutive editions of the newsletter across that period, more often than any other ingredient it covered. For formulators working on prenatal, glycemic-support, and women’s health formats, the cluster is useful because the dose ranges, populations, and endpoints are stated explicitly in each summary.All4Nutra has previously covered vitamin D as a multi-target intervention across metabolic and neuroinflammatory conditions, and the studies below extend that picture into maternal and perinatal endpoints.
The text inside each quotation is the newsletter’s own wording. Citation markers within the quotations have been renumbered to this article’s source list, and nothing else inside them has been altered.
Study 1: Gestational diabetes: 2000 IU/day over three months
From The Vitamin Professor Newsletter, August 4, 2026, section “Vitamin D supplementation for gestational diabetes” [1]:
Gestational diabetes mellitus (GDM) commonly presents as insulin resistance and altered lipid metabolism, with evidence linking vitamin D deficiency to its pathogenesis. In this randomized, double-blind, placebo-controlled trial [5], 120 pregnant women diagnosed with GDM were assigned to receive either vitamin D3 supplements (2000 IU/day) or a placebo for 3 months. Serum vitamin D status, glycemic control parameters, and lipid profiles were evaluated pre- and post-intervention, adjusting for dietary and exercise confounders. After the 3-month intervention, serum 25-hydroxyvitamin D levels in the vitamin D group were significantly higher than those in the placebo group. Vitamin D supplementation effectively reduced fasting plasma glucose, fasting insulin, and HOMA-IR scores. Simultaneously, it significantly decreased triglycerides and LDL-C levels while increasing HDL-C. Total cholesterol levels showed no statistically significant difference between the two groups. Supplementation with 2000 IU vitamin D per day for 3 months yields significant improvements in glucose homeostasis and lipid metabolism in the GDM population. Vitamin D holds promise as an effective auxiliary treatment to enhance maternal metabolic health.
Study 2: Type 2 diabetes prevention in prediabetes: cost-effectiveness modelling
From The Vitamin Professor Newsletter, July 20, 2026, section “Vitamin D for lowering the risk of type 2 diabetes in adults with prediabetes” [2]:
This microsimulation modelling study [6] assessed the long-term cost-effectiveness of vitamin D supplementation for preventing type 2 diabetes. It included a representative cohort of 10,000 U.S. adults with prediabetes in the National Health and Nutrition Examination Survey (NHANES) 2013–2018 cohort. Treatment effects came from individual-participant data of three randomised trials of vitamin D versus placebo (D2d, USA, 2013–2018; DPVD, Japan, 2013–2019; Tromsø, Norway, 2008–2015; pooled analysis 2023). Cost-effectiveness was measured by an incremental cost-effectiveness ratio (ICER) in terms of cost per quality-adjusted life year (QALY) compared to no vitamin D. Researchers conducted subgroup analyses by age, baseline fasting glucose level, body weight, and family history of diabetes. We performed one-way and probabilistic sensitivity analysis. Costs were in 2024 U.S. dollars. 10-year and lifetime time horizons were studied from a U.S. health care system perspective. Results were that, in a NHANES-derived cohort of 4176 adults with prediabetes (mean age 53.3 years [SD 17.0]; 2024 [49%] female; 2603 [62%] non-Hispanic White, 488 [12%] non-Hispanic Black, 668 [16%] Hispanic, 417 [10%] other race/ethnicity), vitamin D supplementation reduced per-person lifetime costs by $3208 (95% uncertainty interval [UI] −$5974 to $171), increased lifetime QALYs by 0.12 (95% UI 0.05–0.19), and yielded a lifetime net monetary benefit of $15,483 (95% UI $8108–$21,907) at a willingness-to-pay threshold of $100,000/QALY. Life-years gained were 0.27 per person (95% UI 0.06–0.50). Vitamin D reduced the lifetime cumulative incidence of diabetes by 8% (95% UI 6.4–10.6%). Diabetes complications were reduced by an average of 6.4% (95% UI 3.2–8.7%). There were little differences in ICERs across subgroups. Changes in intervention-related parameters had limited effects on the cost-effectiveness ratios across sensitivity analyses, and the intervention likewise remained cost-saving compared to no vitamin D under all simulation scenarios. In conclusion, vitamin D supplementation may be an efficient use of health care resources for preventing type 2 diabetes in adults with prediabetes.
Formats aimed at this population sit alongside other glycemic-support concepts on the portal, including work on a functional beverage for pre-diabetic patients.
Study 3: Vitamin D deficiency in pregnancy: obstetric implications
From The Vitamin Professor Newsletter, June 19, 2026, section “Impact of vitamin D deficiency in pregnant women” [3]:
This review [7] analyzes current evidence regarding vitamin D deficiency during pregnancy from an obstetric perspective, focusing on pregnancy complications, fetal outcomes, and evidence-based supplementation strategies for clinical practice. A systematic review of PubMed, Scopus, and Cochrane databases was conducted, encompassing publications from 2020-2025. Randomized controlled trials, meta-analyses, and prospective cohort studies examining vitamin D status and pregnancy outcomes were included. Analysis demonstrated significant associations between vitamin D deficiency (< 50 nmol/L) and elevated risk of preeclampsia (OR 0.65), gestational diabetes mellitus (OR 1.61), preterm birth (RR 0.67), and small-for-gestational-age neonates (RR 0.61). Supplementation with 2000-4000 IU/day appears safe and efficacious in achieving optimal concentrations. In conclusion, vitamin D assessment and individualized supplementation should be integrated into routine prenatal care. Obstetricians should implement screening protocols particularly for high-risk pregnant women.
Study 4: Perimenopausal fatigue and mood
From The Vitamin Professor Newsletter, May 21, 2026, section “Vitamin D for fatigue and improved mood in perimenopausal women” [4]:
A 6-month, randomized, double-blind, placebo-controlled trial [8] was conducted to investigate the effect of vitamin D supplementation on fatigue and mood in 100 perimenopausal women with vitamin D deficiency. Participants in the intervention group received oral vitamin D₃ at a dose of 60,000 IU once weekly for 8 weeks, followed by 60,000 IU once monthly for the subsequent 4 months. The control group received an identical placebo on the same schedule. Results showed significant improvements in both fatigue and mood in the vitamin D group compared to placebo. The group receiving vitamin D had a 30 percent decrease in fatigue and 39 percent improvement in mood. Multivariate analysis confirmed vitamin D supplementation as a predictor of these improvements. Thus, vitamin D supplementation can effectively alleviate fatigue and improve mood in perimenopausal women with vitamin D deficiency.
Study 5: Prenatal high-dose vitamin D3 and offspring cognition at age 10
From The Vitamin Professor Newsletter, May 21, 2026, section “Vitamin D supplementation during pregnancy for improving offspring cognition at 10 years” [4]:
A post hoc secondary analysis [9] of the blinded, placebo-controlled Copenhagen Prospective Studies on Asthma in Childhood 2010 RCT conducted to assess whether high-dose vitamin D3 supplementation during pregnancy is associated with improved offspring cognition at age 10 years. The cohort included 700 mother-child pairs from Denmark, of whom 623 were randomized. Exclusion criteria included vitamin D intake above 600 IU/d. Cognitive assessments were conducted for the offspring at age 10 years, excluding those born at less than 28 weeks’ gestation and with birth weight less than 1500 g. The intervention was high-dose (2800 IU/d) or standard-dose (400 IU/d) vitamin D3 from pregnancy week 24 to one week post-partum. The primary outcome was cognitive functioning across 11 functions assessed at age 10 years using a comprehensive neuropsychological test battery as part of the Copenhagen Prospective Study on Neuro-Psychiatric Development (COPSYCH). Results were that the vitamin D3 RCT and the COPSYCH visit were completed by 498 children (mean [SD] age, 10.3 [0.4] years; 258 boys [51.8%]): 247 prenatally exposed to high-dose vitamin D3 and 251 prenatally exposed to standard-dose vitamin D3. Covariate-adjusted analyses of standardized scores (mean [SD], 0 [1]; higher values indicating better performance) showed positive associations of high-dose vitamin D3 with verbal memory (P = 0.02), visual memory (P = 0.01), and flexibility or set shift (P = 0.04); however, high-dose vitamin D3 was no longer associated with flexibility or set shift after multiple test correction. In conclusion, this post hoc analysis of an RCT suggests that high-dose vitamin D3 supplementation in pregnancy is positively associated with visual memory, verbal memory, and flexibility or set shift among offspring measured at age 10 years. These findings strengthen evidence on the association of prenatal vitamin D exposure with childhood cognition.
What the dose ranges mean for formulators
The doses stated across these five summaries span daily, weekly, and monthly regimens, so they are not directly interchangeable in a single format decision. The daily protocols reported are 2000 IU/day in gestational diabetes, 2000 to 4000 IU/day in the pregnancy review, and 2800 IU/d against a 400 IU/d comparator in the prenatal cognition analysis, while the perimenopausal trial used 60,000 IU weekly followed by 60,000 IU monthly.
Delivery remains a separate question from dose. Vitamin D3 is fat soluble and poorly water soluble, which is why All4Nutra has covered encapsulation approaches that improved vitamin D3 bioavailability, vitamin D-loaded lipid nanoparticles, and the broader pharmacokinetics of vitamin dosage forms. Readers working on bone-directed formats can also refer to the portal’s overview of nutrients, nutraceuticals, and bone.
About the source publication
The Vitamin Professor Newsletter is published on LinkedIn by Dr. Gene Bruno, DBM, MS, RH(AHG), who states he is a 47-year veteran of the dietary supplement industry, served for 20 of those years as Professor of Nutraceutical Science at Huntington University of Health Sciences, and now serves as Chief Scientific Officer for Nutraland USA. The newsletter is free and published bimonthly, and covers recent research on nutraceuticals.
Alongside the newsletter, Dr. Bruno hosts The Vitamin Professor podcast, which explores the supplement space with industry professionals and focuses on nutraceutical science. Episodes are available on YouTube, Spotify, Apple Podcasts, iHeart, and other podcast platforms. Notifications of new episodes are distributed by email through Vitamin Retailer Industry Partner Offers and Announcements.
These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.
Sources
- Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, August 4, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–3et8c
- Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, July 20, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–61b8c
- Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, June 19, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–8fcgc
- Primary source (original publication): Bruno G. “The Vitamin Professor™ Newsletter,” LinkedIn newsletter, May 21, 2026. https://www.linkedin.com/pulse/vitamin-professor-newsletter-dr-gene-bruno-dbm-ms-rh-ahg–nctmc
- Duan Y, Zhang S, Ma X, Li L, Jia K. Effects of vitamin D supplementation on insulin resistance and lipid metabolic profiles in women with gestational diabetes mellitus: A randomized controlled trial. Afr J Reprod Health. 2026 Aug 3;30(14):86-93. doi: 10.29063/ajrh2026/v30i14.10.
- Briody J, Pittas A, Zhang P, et al. The cost-effectiveness of vitamin D supplementation for the prevention of type 2 diabetes in the United States: a microsimulation modelling study. Lancet Reg Health Am. 2026;61. doi: 10.1016/j.lana.2026.101543.
- Tadros-Zins M, Krekora M, Zych-Krekora K, Drosdzol-Cop A. Vitamin D deficiency in pregnant women: obstetric implications and clinical management. Ginekol Pol. 2026;97(5):422-426. doi: 10.5603/gpl.110273.
- Ray P, Srivastava A, Jani P. Effect of vitamin D supplementation on fatigue and mood among perimenopausal women. Bioinformation. 2026;22(3):1638-1642. doi: 10.6026/973206300221638.
- Frederiksen OF, Jepsen JRM, Brustad N, et al. High-Dose Vitamin D3 Supplementation During Pregnancy and Test-Based Cognitive Performance at Age 10 Years: A Post Hoc Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2026 May 1;9(5):e2611464. doi: 10.1001/jamanetworkopen.2026.11464.
Read more on vitamin D here:
Vitamin D Supplementation as a Multi-Target Intervention
Clinical Insights Across Metabolic and Neuroinflammatory Conditions
